Orient Pharma Co., Ltd.

Research Orient Pharma Co., Ltd. (4166.TWO) on Bullrun: market cap TWD 5.89B, P/E 24.5. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is TWD 5.89B; P/E is 24.5.

Peer valuation comparison

Latest P/E is 24.49x versus a Healthcare sector median of 21.8x (12.4% above).

Latest P/E is 24.49x versus a Taiwan median of 18.67x (31.2% above).

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18TWD 5.89B24.5n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 TWD.

About Orient Pharma Co., Ltd.

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.

Related stock research

Taiwan stocks Taiwan Healthcare stocks A-Z stock index

Other Healthcare stocks

Grape King Bio Ltd (1707.TW) Standard Chemical & Pharmaceutical Co., Ltd. (1720.TW) Maywufa Company Ltd. (1731.TW) Panion & Bf Biotech Inc. (1760.TW) Allied Biotech Corporation (1780.TWO) ScinoPharm Taiwan, Ltd. (1789.TW) Lotus Pharmaceutical Co., Ltd. (1795.TW) GeneFerm Biotechnology Co., Ltd. (1796.TWO) Easywell Biomedicals, Inc. (1799.TWO) LIWANLI Innovation Co., Ltd. (3054.TW) YungShin Global Holding Corporation (3705.TW) TTY Biopharm Company Limited (4105.TWO)

Frequently asked questions

What is Orient Pharma Co., Ltd.'s market cap?

Orient Pharma Co., Ltd.'s market capitalization is TWD 5.89B.

What is Orient Pharma Co., Ltd.'s P/E ratio?

Orient Pharma Co., Ltd.'s price-to-earnings (P/E) ratio is 24.5.

What does Orient Pharma Co., Ltd. do?

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.